CIK 0001662579
- Non-accelerated filer
- Smaller reporting company
C4 Therapeutics, Inc.
Sign in to watch- Ticker
- CCCC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 475617627
- Phone
- +1 617-231-0700
- Business address
- 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $122,487
- in 1 filing, $122K under 10b5-1 plans
Net −$122,487. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-14 | Mahaney Paige Chief Scientific Officer | Option exercise | +7,050 | 339,356 | ||
| 2026-02-14 | Mahaney Paige Chief Scientific Officer | Shares withheld for taxes | −2,446 | $1.89 | $5K | 336,910 |
| 2026-02-13 | Mahaney Paige Chief Scientific Officer | Grant or award | +240,000 | 339,356 | ||
| 2025-10-28 | Mahaney Paige Chief Scientific Officer | Option exercise | +19,200 | 105,000 | ||
| 2025-10-28 | Mahaney Paige Chief Scientific Officer | Shares withheld for taxes | −5,644 | $2.58 | $15K | 99,356 |
| 2025-02-14 | Mahaney Paige Chief Scientific Officer | Grant or award | +28,200 | 105,000 | ||
| 2025-02-14 | Mahaney Paige Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +42,400 | 42,400 | ||
| 2024-10-28 | Mahaney Paige Chief Scientific Officer | Grant or award | +76,800 | 76,800 | ||
| 2024-10-28 | Mahaney Paige Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +345,600 | 345,600 |
Page 1 of 1 · 9 trades